104 related articles for article (PubMed ID: 3680302)
41. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
Rappuoli R; Pizza M; De Magistris MT; Podda A; Bugnoli M; Manetti R; Nencioni L
Immunobiology; 1992 Feb; 184(2-3):230-9. PubMed ID: 1587545
[TBL] [Abstract][Full Text] [Related]
42. [Trial of pertussis toxin activity in vitro on CHO cells].
Spitsyn SV; Drobyshevskaia EI; Gureeva AA
Zh Mikrobiol Epidemiol Immunobiol; 1987 Jun; (6):60-3. PubMed ID: 3630484
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
44. Colonization of Bordetella pertussis clinical isolates that differ by pulsed field gel electrophoresis types in the lungs of naïve mice or mice immunized with the whole-cell pertussis vaccine used in Poland.
Polak M; Zawadka M; Mosiej E; Rabczenko D; Augustynowicz E; Guiso N; Lutyńska A
Arch Immunol Ther Exp (Warsz); 2015 Apr; 63(2):155-60. PubMed ID: 25297678
[TBL] [Abstract][Full Text] [Related]
45. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein.
Carbonetti NH; Artamonova GV; Andreasen C; Dudley E; Mays RM; Worthington ZE
Infect Immun; 2004 Jun; 72(6):3350-8. PubMed ID: 15155640
[TBL] [Abstract][Full Text] [Related]
46. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
Watanabe M; Komatsu E; Abe K; Iyama S; Sato T; Nagai M
Vaccine; 2002 Jan; 20(9-10):1429-34. PubMed ID: 11818163
[TBL] [Abstract][Full Text] [Related]
48. Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin.
Halperin SA; Issekutz TB; Kasina A
J Infect Dis; 1991 Feb; 163(2):355-61. PubMed ID: 1703192
[TBL] [Abstract][Full Text] [Related]
49. Increase in intradermal vascular permeability caused by pertussis toxin from Bordetella pertussis.
Sakuma S; Imagawa Y; Tokunaga E; Ohtomo N
Microbiol Immunol; 1987; 31(6):531-9. PubMed ID: 2890084
[TBL] [Abstract][Full Text] [Related]
50. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
51. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
Blennow M; Granström M; Jäätmaa E; Olin P
Pediatrics; 1988 Sep; 82(3):293-9. PubMed ID: 3043367
[TBL] [Abstract][Full Text] [Related]
52. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis.
Black WJ; Munoz JJ; Peacock MG; Schad PA; Cowell JL; Burchall JJ; Lim M; Kent A; Steinman L; Falkow S
Science; 1988 Apr; 240(4852):656-9. PubMed ID: 2896387
[TBL] [Abstract][Full Text] [Related]
53. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.
Roberts M; Cropley I; Chatfield S; Dougan G
Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847
[TBL] [Abstract][Full Text] [Related]
54. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1347-51. PubMed ID: 2304902
[TBL] [Abstract][Full Text] [Related]
55. Single-step purification of pertussis toxin and its subunits by heat-treated fetuin-sepharose affinity chromatography.
Chong P; Klein M
Biochem Cell Biol; 1989 Jul; 67(7):387-91. PubMed ID: 2477043
[TBL] [Abstract][Full Text] [Related]
56. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
57. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
58. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine.
Li QT; Zhu YZ; Chu JY; Dong K; He P; Feng CY; Hu BY; Zhang SM; Guo XK
Acta Pharmacol Sin; 2006 Nov; 27(11):1487-94. PubMed ID: 17049126
[TBL] [Abstract][Full Text] [Related]
60. [Evaluation of whole-cell and acellular pertussis vaccines effectiveness in clearance of experimental B. pertussis infection in mice].
Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
Med Dosw Mikrobiol; 2007; 59(2):123-35. PubMed ID: 17929410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
